Abstract
In this study, the activity of the δ-opioid receptor subtype-selective agonist, SB 227122, was investigated in a guinea pig model of citric acid-induced cough. Parenteral administration of selective agonists of the δ-opioid receptor (SB 227122), μ-opioid receptor (codeine and hydrocodone), and κ-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED50 values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively. The nonselective opioid receptor antagonist, naloxone (3 mg/kg, i.m.), attenuated the antitussive effects of codeine or SB 227122, indicating that the antitussive activity of both compounds is opioid receptor-mediated. The δ-receptor antagonist, SB 244525 (10 mg/kg, i.p.), inhibited the antitussive effect of SB 227122 (20 mg/kg, i.p.). In contrast, combined pretreatment with β-funaltrexamine (μ-receptor antagonist; 20 mg/kg, s.c.) and norbinaltorphimine (κ-receptor antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of μ- and κ-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.). The ς-receptor antagonist rimcazole (3 mg/kg, i.p.) inhibited the antitussive effect of dextromethorphan (30 mg/kg, i.p.), a ς-receptor agonist, but not that of SB 227122. These studies provide compelling evidence that the antitussive effects of SB 227122 in this guinea pig cough model are mediated by agonist activity at the δ-opioid receptor.
Footnotes
-
Send reprint requests to: Dr. David C. Underwood, Department of Pulmonary Pharmacology, UW2532, SmithKline Beecham Pharmaceuticals, 709 Swedeland Rd., King of Prussia, PA 19406. E-mail:david_c_underwood{at}sbphrd.com
- Abbreviations:
- DAMGO
- d-Ala2-Me-Phe4-Gly-ol5-enkephalin
- h-DOR
- human δ-opioid receptor
- h-MOR
- human μ-opioid receptor
- h-KOR
- human κ-opioid receptor
- β-FNA
- β-funaltrexamine
- Nor-BNI
- norbinaltorphimine
- CHO
- Chinese hamster ovary
- HEK-293
- human embryonic kidney 293
- RT-PCR
- reverse-transcription polymerase chain reaction
- DADLE
- d-Ala2-d-Leu5-enkephalin
- S.A.
- specific activity
- PLSD
- protected least-squares difference
- Received July 30, 1999.
- Accepted November 1, 1999.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|